These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 20594138)

  • 1. Use of immunomodulators and biologic therapies in children with inflammatory bowel disease.
    Bousvaros A
    Expert Rev Clin Immunol; 2010 Jul; 6(4):659-66. PubMed ID: 20594138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Biological therapy as treatment of inflammatory bowel diseases].
    Agnholt J
    Ugeskr Laeger; 2008 Jun; 170(24):2152-6. PubMed ID: 18565302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.
    Schneeweiss S; Korzenik J; Solomon DH; Canning C; Lee J; Bressler B
    Aliment Pharmacol Ther; 2009 Aug; 30(3):253-64. PubMed ID: 19438424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis.
    Hibi T; Iwao Y; Yajima T; Inoue N; Ueno Y; Takaishi H; Watanabe M; Ishii H
    J Gastroenterol; 1995 Nov; 30 Suppl 8():121-3. PubMed ID: 8563872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of inflammatory bowel disease in adults.
    Katz JA
    J Dig Dis; 2007 May; 8(2):65-71. PubMed ID: 17532817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory bowel disease therapy: current state-of-the-art.
    Blonski W; Buchner AM; Lichtenstein GR
    Curr Opin Gastroenterol; 2011 Jul; 27(4):346-57. PubMed ID: 21654383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical management of patients with difficult-to-treat inflammatory bowel disease.
    van Hogezand RA
    Neth J Med; 1994 Aug; 45(2):55-9. PubMed ID: 7936006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
    Markowitz J; Grancher K; Mandel F; Daum F
    Am J Gastroenterol; 1993 Jan; 88(1):44-8. PubMed ID: 8420272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: chronic active disease and maintaining remission in Crohn's disease.
    Kamm MA
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():102-5. PubMed ID: 15352904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppressive therapy of inflammatory bowel disease: a historical perspective.
    Korelitz BI
    Gastroenterologist; 1995 Jun; 3(2):141-52. PubMed ID: 7640945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
    Roblin X; Serre-Debeauvais F; Phelip JM; Faucheron JL; Hardy G; Chartier A; Helluwaert F; Bessard G; Bonaz B
    Aliment Pharmacol Ther; 2005 Apr; 21(7):829-39. PubMed ID: 15801918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all.
    Melmed GY; Spiegel BM; Bressler B; Cheifetz AS; Devlin SM; Harrell LE; Irving PM; Jones J; Kaplan GG; Kozuch PL; Velayos FS; Baidoo L; Sparrow MP; Siegel CA
    Clin Gastroenterol Hepatol; 2010 Aug; 8(8):655-9. PubMed ID: 20451665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: monitoring of immunomodulators in inflammatory bowel disease.
    Aberra FN; Lichtenstein GR
    Aliment Pharmacol Ther; 2005 Feb; 21(4):307-19. PubMed ID: 15709982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on idiopathic colitides.
    Strobel S; Abreu MT
    Curr Opin Gastroenterol; 2013 Jan; 29(1):60-5. PubMed ID: 23207597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are patients with inflammatory bowel disease receiving optimal care?
    Reddy SI; Friedman S; Telford JJ; Strate L; Ookubo R; Banks PA
    Am J Gastroenterol; 2005 Jun; 100(6):1357-61. PubMed ID: 15929770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing complicated Crohn's disease in children and adolescents.
    Homan M; Baldassano RN; Mamula P
    Nat Clin Pract Gastroenterol Hepatol; 2005 Dec; 2(12):572-9. PubMed ID: 16327836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity of infliximab in the course of treatment of Crohn's disease.
    Bratcher JM; Korelitz BI
    Expert Opin Drug Saf; 2006 Jan; 5(1):9-16. PubMed ID: 16370952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of biologic agents in the treatment of inflammatory bowel disease.
    Shepela C
    Minn Med; 2008 Jun; 91(6):42-5. PubMed ID: 18616021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-Mercaptopurine and other immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis.
    Present DH
    Gastroenterol Clin North Am; 1989 Mar; 18(1):57-71. PubMed ID: 2646222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.